Nancy Tests SPARC-931-part

Generate a summary of this article
Listen to this article
Beta
  
breaking news
scream

With the upcoming patent expirations in oncology biologics, biosimilar developers must act quickly to capitalize on ADCs and BsAbs.

In Vivo Outlook 2024
Outlook 2024 PDF Cover

In this article, explore the opportunities and challenges shaping the landscape, including:

  • How patent expirations, and a shift from monoclonal antibodies, is driving opportunities for biosimilar innovation in ADCs and BsAbs
  • Why the structural complexities of ADCs and BsAbs require new bioanalytical tools and manufacturing processes
  • The evolving regulatory landscape: EMA, FDA and WHO are developing regulatory pathways with flexibility, but challenges still remain
  • The global market forecast, opportunity and key timelines - but why sponsors must act fast
  • How biosimilars can deliver cost savings of $54 billion over the next decade, while broadening patient access to cancer treatments
  • And more

Download the article now: Preparing For The Bhttps://insights-content-arcxp-tst.s3.us-east-1.amazonaws.com/d0a336e6-698f-4356-9dbc-a14b20fc425b_2398846662.pdfiosimilar Era Of ADCs And BsAbs In Oncology

Download

download article 2

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Trial Results

Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

 
• By Xu Hu

Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Sponsored By:

Nancy Tests SPARC-931-part

The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

Primal Pictures

GB-Business-Free: ‘Content’ article that includes different Composer content published on 4 Dec after the BIOME redeployment...

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.